18:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7 billion...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
20:52 , Jun 29, 2018 |  BC Extra  |  Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7 billion...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
20:42 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Novartis details brolucizumab wet AMD data

In a media briefing, Novartis AG (NYSE:NVS; SIX:NOVN) detailed secondary endpoint data from the Phase III HAWK and HARRIER trials of brolucizumab (RTH258) to treat wet age-related macular degeneration (AMD) and touted the candidate's potential...
23:36 , Nov 10, 2017 |  BC Extra  |  Clinical News

Novartis details brolucizumab wet AMD data

In a media briefing Friday, Novartis AG (NYSE:NVS; SIX:NOVN) detailed secondary endpoint data from the Phase III HAWK and HARRIER trials of brolucizumab (RTH258) to treat wet age-related macular degeneration (AMD) and touted the candidate's...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
04:12 , Sep 16, 2017 |  BioCentury  |  Strategy

Passing the baton

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent...
23:40 , Jul 7, 2017 |  BioCentury  |  Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
20:37 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

Novartis' wet AMD therapy non-inferior to Eylea

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from the 96-week Phase III HAWK and HARRIER trials in a total of over 1,800 patients with neovascular wet age-related macular degeneration (AMD) showing that intravitreal brolucizumab (RTH258) met...